MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
AbbVie ROCE Ratio 2011-2025 | ABBV
Annual ROCE Ratio AbbVie
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 274.8 | 123.14 | 104.8 | 116.12 | 86.76 | 17.66 | 15.16 | 17.72 | 16.66 | 17.88 | 21.12 | 25.38 | 28.75 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 274.8 | 15.16 | 66.61 |
Quarterly ROCE Ratio AbbVie
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2420.39 | -2289.71 | 419.37 | 175.29 | 147.18 | 109.37 | 103.32 | 113.24 | 100.68 | 80.07 | 111.78 | 114.78 | 127.68 | 96.98 | 121.87 | 115.05 | 85.46 | 58.2 | 26.17 | -30.74 | -78.1 | -110.46 | -147.86 | -153.24 | -144.34 | -104.48 | -51.62 | 38.64 | 123.56 | 152.31 | 203.23 | 201.31 | 200.57 | 151.55 | 199.34 | 196.19 | 191.65 | 137.49 | 192.6 | 199.93 | 239.95 | 219.63 | 250.15 | 225.57 | 170.94 | 91.92 | -364.08 | -850.6 | -1289.23 | -1141.71 | -1141.71 | -685.71 | -279.43 | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 419.37 | -2420.39 | -109.25 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
Pharming Group N.V.
PHAR
|
281.39 | $ 17.91 | -1.0 % | $ 7.59 B |  Niderland |
 |
Arbutus Biopharma Corporation
ABUS
|
-73.67 | $ 4.78 | -0.31 % | $ 793 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
-91.24 | $ 3.03 | -0.49 % | $ 234 M |  USA |
 |
InflaRx N.V.
IFRX
|
-24.77 | $ 1.09 | -4.82 % | $ 152 M | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
-40.28 | - | - | $ 1.01 B | USA |
 |
Alpine Immune Sciences
ALPN
|
-32.41 | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-57.76 | - | 4.14 % | $ 49.1 M | USA |
 |
Midatech Pharma plc
MTP
|
-337.43 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M |  France |
 |
Ampio Pharmaceuticals
AMPE
|
-75.24 | - | -11.43 % | $ 502 K | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Molecular Transport
AMTI
|
-209.11 | - | - | $ 10.1 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-45.89 | $ 209.39 | -1.61 % | $ 5 B |  Danmark |
 |
Aptevo Therapeutics
APVO
|
-517.39 | $ 0.6 | -35.8 % | $ 166 K | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-104.38 | $ 3.12 | 0.81 % | $ 7.51 B |  Australia |
 |
BioVie
BIVI
|
-95.03 | $ 1.2 | -5.51 % | $ 1.77 M | USA |
 |
Athersys
ATHX
|
-531.85 | - | 3.77 % | $ 22.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
Avenue Therapeutics
ATXI
|
-403.4 | - | -52.27 % | $ 4.45 M | USA |
 |
ARCA biopharma
ABIO
|
-23.06 | - | 1052.0 % | $ 415 M | USA |
 |
AVROBIO
AVRO
|
10.76 | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-115.03 | $ 0.22 | 24.46 % | $ 479 M |  Israel |
 |
Acasti Pharma
ACST
|
-25.04 | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-353.66 | - | -15.15 % | $ 60.3 M | Britain |
 |
BioDelivery Sciences International
BDSI
|
19.77 | - | -4.8 % | $ 255 M | USA |
 |
Albireo Pharma
ALBO
|
-70.32 | - | -0.23 % | $ 916 M | USA |
 |
BioNTech SE
BNTX
|
-4.81 | $ 94.72 | -0.33 % | $ 27.2 B | Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
28.05 | $ 27.09 | 1.04 % | $ 1.31 B | USA |
 |
BeiGene, Ltd.
BGNE
|
-15.33 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Anika Therapeutics
ANIK
|
-41.29 | $ 9.6 | 1.27 % | $ 141 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-1339.01 | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-69.03 | - | -7.31 % | $ 87 M | USA |
 |
bluebird bio
BLUE
|
-125.56 | - | - | $ 546 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-92.73 | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
146.85 | - | 2.71 % | $ 14 M | USA |
 |
Calithera Biosciences
CALA
|
-1377.15 | - | -10.95 % | $ 876 K | USA |
 |
Axon Enterprise
AXON
|
2.51 | $ 584.81 | -1.07 % | $ 44.3 B | USA |
 |
Cellectar Biosciences
CLRB
|
257.01 | $ 2.53 | -8.33 % | $ 30.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3412.47 | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-12.81 | $ 2.44 | -3.56 % | $ 15.3 M | USA |
 |
AstraZeneca PLC
AZN
|
11.12 | $ 92.79 | 0.37 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
167.74 | - | -24.86 % | $ 820 K | USA |
 |
Catalyst Biosciences
CBIO
|
424.75 | $ 12.33 | -0.29 % | $ 812 M | USA |
 |
Brickell Biotech
BBI
|
-64.05 | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
14.24 | $ 9.1 | 1.0 % | $ 1.48 B | Britain |
 |
Celldex Therapeutics
CLDX
|
-26.11 | $ 26.29 | -2.01 % | $ 1.69 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
95.22 | $ 11.07 | 2.45 % | $ 716 M | USA |